Norwegian biotech company Calanus, which develops, manufactures and sells health food products derived from the marine copepod Calanus finmarchicus, is working towards a possible listing of shares on Euronext Growth.
Gunnar Rorstad, who has led Calanus since its inception, will lead the company through this process, after which Siv-Katrin Ramskjell will become the new CEO on June 1.
Rorstad wants to step down to focus on his own projects in the years ahead.
Ramskjell has been commercial director at Calanus since the fall of 2020.
She has extensive experience with brand building in the Nordic region, and has been responsible for sales and business development of several major international brands.
"She appears as a very skilled leader, with documented financial results and relevant background with regard to the exciting commercial opportunities Calanus AS is now working to realize," said Stig Ebert Nilssen, charman of the board, in a statement.
Ramskjell will start the work of strengthening the organization with a view toward growth by hiring more employees in positions within sales and marketing.